Endothelin receptor antagonists, particularly nonpeptide ETA-selective agents, show preclinical promise for treating cardiovascular and renal conditions.
Preclinical data on ETA antagonists in CV/renal disease warrant human trials; leaves open clinical translation and safety.
Data from animal models indicate that endothelin (ET) receptor antagonists may have therapeutic utility in hypertension, myocardial infarction and subsequent reperfusion injury, acute renal failure and asthma. Selective antagonists for the two receptor subtypes (ETa and ETb) are now available. Nonpeptide ETA-selective antagonists are now available and have the potential of developing into orally active agents in clinical studies.
No takes yet. Share an insight, caveat, or question.
Kazumi Shiosaki (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: